<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H8C9E048B6F314317934136716DD79333" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>118 HR 6465 IH: Preserving Life-saving Access to Specialty Medicines in America Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2023-11-21</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">118th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 6465</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20231121">November 21, 2023</action-date><action-desc><sponsor name-id="H001067">Mr. Hudson</sponsor> (for himself, <cosponsor name-id="M001210">Mr. Murphy</cosponsor>, <cosponsor name-id="D000230">Mr. Davis of North Carolina</cosponsor>, and <cosponsor name-id="N000194">Mr. Nickel</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the Committee on <committee-name committee-id="HWM00">Ways and Means</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned</action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend title XVIII of the Social Security Act to provide a phase-in for plasma-derived products under the manufacturer discount program.</official-title></form><legis-body id="H16BAD2331A024EC19B01564592BCC722" style="OLC"><section id="H582035D3EDC448DBA7B0C7B2071FE536" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Preserving Life-saving Access to Specialty Medicines in America Act</short-title></quote> or the <quote><short-title>PLASMA Act</short-title></quote>.</text></section><section id="H03B42DB74F9D46089AFB9952B6BE31DD" section-type="subsequent-section"><enum>2.</enum><header>Phase-in for plasma-derived products under manufacturer discount program</header><text display-inline="no-display-inline">Section 1860D–14C(g)(4) of the Social Security Act (42 U.S.C. 1395w–114c(g)(4)) is amended—</text><paragraph commented="no" display-inline="no-display-inline" id="H9D70274072FD456ABE3F4BC4C5C7F1B0"><enum>(1)</enum><text>in subparagraph (A), in the matter preceding clause (i), by striking <quote>and (C)</quote> and inserting <quote>, (C), and (D)</quote>;</text></paragraph><paragraph id="H82390B5EBB294333A955883204292F8D"><enum>(2)</enum><text>by redesignating subparagraphs (D) and (E) as subparagraphs (E) and (F), respectively; and</text></paragraph><paragraph id="H8525FFF15A6A4D4680E3ADD87E18909C"><enum>(3)</enum><text>by inserting after subparagraph (C) the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="HD53D8C224E0E47F186853E4F9A957859"><subparagraph id="H63D60D9E8A134F649B31542A04F2C851"><enum>(D)</enum><header>Phase-in for plasma-derived products</header><clause id="H0746FC1BABDB4E9AAE580B32170B11F3"><enum>(i)</enum><header>In general</header><text>In the case of an applicable drug that is a plasma-derived product (as defined in clause (ii)), and that is marketed as of the date of enactment of this subparagraph and dispensed for an applicable beneficiary, the term <term>discounted price</term> means the specified plasma-derived product percent (as defined in clause (iii)) of the negotiated price of the applicable drug of the manufacturer.</text></clause><clause id="HF5D03CFA15E442D09F1453A5098F2640"><enum>(ii)</enum><header>Plasma-derived product</header><text>In this subparagraph, the term <term>plasma-derived product</term> means an applicable drug that is a biological product that is derived from human whole blood or plasma.</text></clause><clause id="H542060105CA44F3198156D6BCF6431A9"><enum>(iii)</enum><header>Specified plasma-derived product percent</header><text>In this subparagraph, the term <term>specified plasma-derived product percent</term> means, with respect to a year—</text><subclause id="H262FC2DFA16F4719BC058B438349E74B"><enum>(I)</enum><text>for an applicable drug that is as a plasma-derived product dispensed for an applicable beneficiary who has not incurred costs, as determined in accordance with section 1860D–2(b)(4)(C), for covered part D drugs in the year that are equal to or exceed the annual out-of-pocket threshold specified in section 1860D–2(b)(4)(B)(i) for the year, the percent specified under subparagraph (B)(iii)(I) for such year; and</text></subclause><subclause id="HA9600BB309E642E1A82322072E47EB1F"><enum>(II)</enum><text>for an applicable drug that is as a plasma-derived product dispensed for an applicable beneficiary who has incurred costs, as determined in accordance with section 1860D–2(b)(4)(C), for covered part D drugs in the year that are equal to or exceed the annual out-of-pocket threshold specified in section 1860D–2(b)(4)(B)(i) for the year, the percent specified under subparagraph (B)(iii)(II) for such year.</text></subclause></clause></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></section></legis-body></bill> 

